Free Trial

Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday

Invivyd logo with Medical background

Invivyd (NASDAQ:IVVD - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $34.45 million for the quarter.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million for the quarter, compared to analysts' expectations of $13.57 million. On average, analysts expect Invivyd to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Invivyd Trading Down 1.1 %

Invivyd stock traded down $0.01 on Tuesday, hitting $0.57. 110,289 shares of the stock traded hands, compared to its average volume of 4,274,882. Invivyd has a 1 year low of $0.35 and a 1 year high of $2.74. The firm has a market cap of $68.26 million, a P/E ratio of -0.29 and a beta of 0.40. The business's fifty day simple moving average is $0.69 and its 200 day simple moving average is $0.77.

Wall Street Analysts Forecast Growth

IVVD has been the topic of a number of analyst reports. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of Invivyd in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Invivyd in a report on Wednesday, March 26th.

Read Our Latest Report on IVVD

About Invivyd

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

See Also

Earnings History for Invivyd (NASDAQ:IVVD)

Should You Invest $1,000 in Invivyd Right Now?

Before you consider Invivyd, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.

While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines